Research programme: CD137 agonists - Bicycle Therapeutics

Alternative Names: BCY 3814

Latest Information Update: 23 Apr 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Bicycle Therapeutics
Class Antineoplastics; Drug conjugates; Peptides
Mechanism of Action CD137 antigen agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

21 Apr 2018 Preclinical trials in Cancer in USA (unspecified route)
21 Apr 2018 Interim pharmacodynamics data from preclinical studies in Cancer presented at the 109^th Annual Meeting of the American Association for Cancer Research (AACR-2018)
03 Apr 2018 Early research in Cancer in USA before April 2018

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.